1. Amidon GL, Lennernäs H, Shah VP, Crison JR. “A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability”. In: Pharm Res 12.3 (1995), pp. 413–20. [Journal Article].
2. Wu C, Benet L. “Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system”. In: Pharm Res 22.1 (2005), pp. 11–23. [Journal Article].
3. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Guidance for Industry U.S. Department of Health and Human Services. 2017. [Scientific Guideline].
4. European Medicines Agency. Committee for medicinal products for human use (CHMP) Guideline on the investigation of bioequivalence. London, Jan. 2017.[Scientific Guideline].
5. Charalabidis A, Sfouni M, Bergström C, Macheras P. “BCS and BDDCS: Beyond guidelines”. In: International Journal of Pharmaceutics (2019), 566:264–281. [Journal Article].